Clinical Trial Update: Zidovudine and Lamivudine Given Once Versus Twice Daily [Phase 1]

View source ↗

Summary

Phase 1 study comparing once-daily versus twice-daily dosing of zidovudine and lamivudine in HIV infections; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lamivudine (lamivudine)
• Zidovudine (Zidovudine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED